217 related articles for article (PubMed ID: 29649593)
41. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
[TBL] [Abstract][Full Text] [Related]
42. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza.
Vajdy M; Baudner B; Del Giudice G; O'Hagan D
Clin Immunol; 2007 May; 123(2):166-75. PubMed ID: 17349825
[TBL] [Abstract][Full Text] [Related]
43. Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity.
Mizuno D; Kimoto T; Takei T; Fukuta A; Shinahara W; Takahashi E; Yano M; Kido H
Vaccine; 2011 Jul; 29(33):5368-78. PubMed ID: 21669246
[TBL] [Abstract][Full Text] [Related]
44. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
45. A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.
Jones T; Allard F; Cyr SL; Tran SP; Plante M; Gauthier J; Bellerose N; Lowell GH; Burt DS
Vaccine; 2003 Sep; 21(25-26):3706-12. PubMed ID: 12922101
[TBL] [Abstract][Full Text] [Related]
46. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
[TBL] [Abstract][Full Text] [Related]
47. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice.
Kimoto T; Kim H; Sakai S; Takahashi E; Kido H
Vaccine; 2019 Jan; 37(4):612-622. PubMed ID: 30553569
[TBL] [Abstract][Full Text] [Related]
48. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
Strindelius L; Filler M; Sjöholm I
Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
[TBL] [Abstract][Full Text] [Related]
49. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
Madhun AS; Haaheim LR; Nøstbakken JK; Ebensen T; Chichester J; Yusibov V; Guzman CA; Cox RJ
Vaccine; 2011 Jul; 29(31):4973-82. PubMed ID: 21600260
[TBL] [Abstract][Full Text] [Related]
50. A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization.
Ben-Yedidia T; Beignon AS; Partidos CD; Muller S; Arnon R
Mol Immunol; 2002 Oct; 39(5-6):323-31. PubMed ID: 12220890
[TBL] [Abstract][Full Text] [Related]
51. Membrane-anchored stalk domain of influenza HA enhanced immune responses in mice.
Gao D; Chen Y; Han D; Qi Q; Sun X; Zhang H; Feng H; Wang M
Microb Pathog; 2017 Dec; 113():421-426. PubMed ID: 29174687
[TBL] [Abstract][Full Text] [Related]
52. Intranasally administered polyethylenimine adjuvanted influenza M2 ectodomain induces partial protection against H9N2 influenza A virus infection in chickens.
Hajam IA; Kim J; Lee JH
Vet Immunol Immunopathol; 2019 Mar; 209():78-83. PubMed ID: 30885310
[TBL] [Abstract][Full Text] [Related]
53. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
[TBL] [Abstract][Full Text] [Related]
54. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
[TBL] [Abstract][Full Text] [Related]
55. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants.
Samdal HH; Bakke H; Oftung F; Holst J; Haugen IL; Korsvold GE; Kristoffersen AC; Krogh G; Nord K; Rappuoli R; Berstad AK; Haneberg B
Hum Vaccin; 2005; 1(2):85-90. PubMed ID: 17038826
[TBL] [Abstract][Full Text] [Related]
56. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
57. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM
Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234
[TBL] [Abstract][Full Text] [Related]
58. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.
Periwal SB; Kourie KR; Ramachandaran N; Blakeney SJ; DeBruin S; Zhu D; Zamb TJ; Smith L; Udem S; Eldridge JH; Shroff KE; Reilly PA
Vaccine; 2003 Jan; 21(5-6):376-85. PubMed ID: 12531635
[TBL] [Abstract][Full Text] [Related]
59. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
[TBL] [Abstract][Full Text] [Related]
60. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
